Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report)'s stock had its "outperform" rating restated by investment analysts at William Blair in a report issued on Wednesday,RTT News reports.
A number of other equities analysts have also weighed in on the company. HC Wainwright began coverage on Telix Pharmaceuticals in a research note on Thursday, July 3rd. They issued a "buy" rating and a $23.00 price objective for the company. Wedbush reaffirmed an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Thursday, June 12th.
View Our Latest Stock Analysis on Telix Pharmaceuticals
Telix Pharmaceuticals Price Performance
NASDAQ:TLX traded up $1.23 during mid-day trading on Wednesday, hitting $16.92. 105,223 shares of the company traded hands, compared to its average volume of 29,148. The stock's fifty day moving average price is $16.78 and its 200-day moving average price is $16.95. Telix Pharmaceuticals has a one year low of $13.61 and a one year high of $30.36. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.66 and a current ratio of 2.78.
Hedge Funds Weigh In On Telix Pharmaceuticals
An institutional investor recently bought a new position in Telix Pharmaceuticals stock. Private Advisor Group LLC purchased a new position in Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 10,140 shares of the company's stock, valued at approximately $170,000.
Telix Pharmaceuticals Company Profile
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Articles
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
